Arrowhead Research, the parent firm of Calando Pharmaceuticals, has added three executives to its management team.
The company has appointed Thomas Haag as its chief patent officer, Mark Tilley as its vice president of advanced materials, and James Hamilton as its vice president of medical technologies.
Haag was previously a practicing lawyer at the law firm Kenyon & Kenyon. He holds a BS in biology and a PhD in molecular, cell, and developmental biology from the University of California, Los Angeles.
Tilley joins Arrowhead from DSM, a Dutch specialty performance materials and life science firm, where he most recently served as senior investment manager with the company’s venture arm. He holds a BS in chemistry from the University of Manchester Institute of Science and Technology, as well as a PhD from North Dakota State University and an MBA from Pepperdine.
Hamilton is co-founder of NanoValent Pharmaceuticals, a nanoparticle vaccine delivery firm, and has worked as a biotech analyst at Reservoir Ventures. He holds an MD from Ohio State University and an MBA from the Fisher College of Business at Ohio State.
Robert Brown, a Harvard Medical School researcher and member of CytRx’s scientific advisory board, has been appointed chair of the school’s department of neurology.
Brown has conducted groundbreaking work investigating amyotrophic lateral sclerosis and was part of the team that identified the mutation responsible for the familial form of the disease. He has also collaborated with UMMS researcher Zuoshang Xu on the development of RNAi-based strategies for treating familial ALS. That work is currently being pursued by RXi Pharmaceuticals, a spin out of CytRx.